News

A new Q&A focuses on hybrid telehealth in ophthalmology and subspecialty-level care, and its potential to create new opportunities and increase access for patients.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

With the population aging, there is a need for new treatments in nephrology.

Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy's benefit, and her original premise. Her team's phase 3 trial evaluating Arg is currently underway.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.

Meta-analysis data show female, Black and Asian participants are generally underrepresented across studies assessing COVID-19 prevention or treatment strategies.

The indication makes tocilizumab the first monoclonal antibody to be granted full FDA approval to treat the pandemic virus.

Lawrence Eichenfield, MD, reviews major drug approvals and advancement of screening and prevention strategies for the youngest patients with atopic dermatitis.

Dr. Adam Lamble shares that outcomes for pediatric patients with acute myeloid leukemia that have TP53 status are inferior to other patients with high-risk disease.

Dr. Corinna Schultz talks about her latest data and the growing body of literature showing medical complications that can come with sickle cell trait.

With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.

A continued discussion with Dr. Bays on anti-obesity therapies down the line and where they might be in the near future.

Anti-obesity medications have the potential for significant weight reduction, but the development of newer agents may lead to an even greater change in obesity care.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

"Using CRISPR/Cas9 you are able to actually fix a disease, that otherwise, was not fixable," Dr. Haydar Frangoul explains the data he presented at ASH 2022.

As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.

A moderate negative correlation was observed between changes in BCVA and changes in CST at weeks 12 and 24.

Some in the industry expect the Adderall shortage to possibly last until March 2023.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

Dupilumab use surpassed all conventional systemic drug use since its introduction in 2017 until the end of the study in 2020-21.

Serotonin syndrome occurred in less than 0.5% of patients, while the number of serotonin syndrome cases was fewer in the antidepressant group.

New data revealed the amount of collective physician work hours in the US has been consistently declining for 20 years.

Research on patients with generalized pustular psoriasis or erythrodermic psoriasis showed positive results for risankizumab.

New surveillance data from the 2021-22 influenza show the impact of coinfection among younger patients.

A recent study highlighted psoriasis patients' lack of awareness of a link between psoriasis and obesity, as well as these same patients' hopes for future treatment programs targeting weight loss.

The ERF and ERF-free groups had similar best visual acuity gains from baseline to week 52.

Patients with DR who received intravitreal anti-VEGF injections had a risk of cardiovascular events similar to those who received laser or steroid treatment

The results show significant LSM relative reductions compared to pooled placebo in aspartate aminotransferase for pegozafermin 3 mg once weekly, 27 mg once weekly, and 36 mg once every 2 weeks.

American Lung Association's Jennifer Folkenroth discusses the issues with "cold turkey," and what every habitual smoker should look for in a cessation plan.

New developments in gene therapy offer a promising perspective of a future where curing sickle cell disease (SCD) is possible.